by Team Attomarker | Jun 10, 2025 | Long Covid
The Immune Response to SARS-CoV-2 and Long COVID Long COVID is currently reported to affect as many as one in five individuals who have had a COVID infection in the UK, with each new SARS-CoV-2 infection adding to the risk burden of developing the debilitating...
by Team Attomarker | Apr 9, 2025 | Long Covid
EXETER, UK – 4 April 2025 – Attomarker, a leader in rapid diagnostic technology, today announced its plans for a new study evaluating the use of AstraZeneca’s monoclonal antibody, Sipavibart (Kavigale), as a potential treatment for long COVID patients. Long COVID...
by Team Attomarker | Mar 13, 2025 | Long Covid
International Long COVID Awareness Day 2025 Five Years On, Long COVID Patients Are Still Being Left Behind On 15th March we mark five years since the start of the pandemic and with it, International Long COVID Awareness Day. While COVID-19 may have faded from...
by Team Attomarker | May 18, 2023 | Long Covid
A Novel Diagnosis and Treatment TO BOOK YOUR ANTIBODY IMMUNITY SPECTRUM TEST: longcovid@re-cognitionhealth.comElimination of a SARS-CoV-2 infection requires both antibody and T cells for complete clearance of the coronavirus from the localised infection site. Systemic...
by Team Attomarker | Sep 22, 2022 | Viewpoints
Schools have returned About a month ago, schools returned for the 2022/23 academic year. This will expose many teachers and students to viruses brought home from summer holidays and socialising with family and friends. These viruses include the new Omicron variants of...
